Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down before the market opened on Wednesday . The stock had previously closed at $53.52, but opened at $48.90. Zealand Pharma A/S shares last traded at $48.90, with a volume of 179 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, BNP Paribas Exane downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Zealand Pharma A/S has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Down 9.4%

The business has a fifty day moving average of $46.42 and a two-hundred day moving average of $62.50. The company has a market cap of $3.50 billion, a price-to-earnings ratio of 3.63 and a beta of 0.87. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. The business had revenue of $5.33 million during the quarter, compared to analyst estimates of $2.81 million. Zealand Pharma A/S had a return on equity of 41.50% and a net margin of 68.82%. As a group, equities analysts anticipate that Zealand Pharma A/S will post 2.7 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.